Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 22:12:749685.
doi: 10.3389/fmicb.2021.749685. eCollection 2021.

Biofilm-Related Infections in Gram-Positive Bacteria and the Potential Role of the Long-Acting Agent Dalbavancin

Alessandra Oliva  1 , Stefania Stefani  2 , Mario Venditti  1 , Enea Gino Di Domenico  3
Affiliations
Review

Biofilm-Related Infections in Gram-Positive Bacteria and the Potential Role of the Long-Acting Agent Dalbavancin

Alessandra Oliva et al. Front Microbiol. .

Abstract

Infections caused by Gram-positive bacteria are a major public health problem due to their increasing resistance to antibiotics. Staphylococcus and Enterococcus species' resistance and pathogenicity are enhanced by their ability to form biofilm. The biofilm lifestyle represents a significant obstacle to treatment because bacterial cells become highly tolerant to a wide range of antimicrobial compounds normally effective against their planktonic forms. Thus, novel therapeutic strategies targeting biofilms are urgently needed. The lipoglycopeptide dalbavancin is a long-acting agent for treating acute bacterial skin and skin structure infections caused by a broad range of Gram-positive pathogens. Recent studies have shown promising activity of dalbavancin against Gram-positive biofilms, including methicillin-resistant S. aureus (MRSA), methicillin-resistant S. epidermidis (MRSE), and vancomycin-susceptible enterococci. This review outlines the mechanisms regulating biofilm development in Staphylococcus and Enterococcus species and the clinical impact of biofilm-related infections. In addition, it discusses the clinical implications and potential therapeutic perspectives of the long-acting drug dalbavancin against biofilm-forming Gram-positive pathogens.

Keywords: Gram-positive; Staphylococcus aureus; biofilm; dalbavancin; skin; soft tissue infections.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Abad L., Josse J., Tasse J., Lustig S., Ferry T., Diot A., et al. (2020). Antibiofilm and intraosteoblastic activities of rifamycins against Staphylococcus aureus: promising in vitro profile of rifabutin. J. Antimicrob. Chemother. 75 1466–1473. 10.1093/jac/dkaa061 - DOI - PubMed
    1. Agarwal A., Kelkar A., Agarwal A. G., Jayaswal D., Schultz C., Jayaswal A., et al. (2020). Implant Retention or Removal for Management of Surgical Site Infection After Spinal Surgery. Global Spine J. 10 640–646. 10.1177/2192568219869330 - DOI - PMC - PubMed
    1. Albano M., Karau M. J., Greenwood-Quaintance K. E., Osmon D. R., Oravec C. P., Berry D. J., et al. (2019). In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin against Planktonic and Biofilm States of Staphylococci Isolated from Periprosthetic Joint Infection. Antimicrob. Agents Chemother. 63 e00959–19. 10.1128/AAC.00959-19 - DOI - PMC - PubMed
    1. Almangour T. A., Alhifany A. A. (2020). Dalbavancin for the management of osteomyelitis: a major step forward? J. Antimicrob. Chemother. 75 2717–2722. 10.1093/jac/dkaa188 - DOI - PubMed
    1. Almangour T. A., Fletcher V., Alessa M., Alhifany A. A., Tabb D. (2017). Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: a Case Report. Am. J. Case Rep. 18 1315–1319. 10.12659/ajcr.905930 - DOI - PMC - PubMed

LinkOut - more resources